Federal appeals court blocks mail-order access to abortion pill mifepristone

A federal appeals court on Friday blocked the abortion pill mifepristone from being mailed under existing Food and Drug Administration (FDA) rules; The court acknowledged that the move would “have a nationwide impact as a practical matter,” setting up a potential fight over abortion access at the Supreme Court.

The 5th U.S. Circuit Court of Appeals ruling could restrict access to abortion pills nationwide and restore rules that supporters say protect patient safety and government authority, while critics warn it would make access harder even in states where abortion remains legal.

The decision means women must now see a medical professional to get a mifepristone prescription, restoring a requirement that was lifted during the COVID-19 pandemic under former President Joe Biden.

Mifepristone is one of two drugs commonly used in medication abortions and accounts for the majority of abortions in the United States. Research from the Guttmacher Institute.

AS FDA HAS A 6-MONTH REVIEW DEADLINE, the abortion pill MIFEPRISTON WILL CONTINUE TO BE SOLD BY MAIL FOR NOW.

The court’s decision blocks distribution of the drug by mail, effectively halting the pharmacy-based distribution allowed under the FDA’s recent rule changes and requiring the drug to be distributed in person under previous safety protocols.

“It is true that, as the district court noted, a stay of § 705 ‘will have a nationwide effect in practice,'” the court wrote, clearly laying out the far-reaching implications of the decision.

The justices harshly criticized the FDA’s handling of the drug’s safety data; He said the agency had “previously eliminated the requirement to report side effects of mifepristone,” saying it was “unreasonable” to eliminate reporting requirements and then rely on the resulting lack of data to justify expanded access.

The decision also bolstered arguments from pro-life states, including Louisiana, that say federal policy undermines abortion laws.

“Any abortion facilitated by the FDA’s action annuls Louisiana’s ban,” the court wrote, adding that the state’s policy “is that every unborn child [a] human beings… from the moment of fertilization.

REPUBLICAN SENATORS oppose FDA over expanding access to abortion pills

Pro-life demonstrators march to the Supreme Court for the annual March for Life in Washington, DC in 2025. (Bryan Dozier/Middle East Images/AFP via Getty Images, File)

“The sovereign privilege of protecting unborn life, once lost, cannot be regained.”

The decision marks a major escalation in the legal battle over abortion drugs, with the Supreme Court likely to reinstate Roe v. in 2022. His decision overturning the Wade case pits federal regulators against states trying to enforce stricter abortion laws.

Pro-life groups were quick to praise the decision.

“This is the win we’ve been waiting for and we pray it stays that way,” said Students for Life President Kristan Hawkins.

“We cannot remain the United States of America if abortion-loving states allow criminal organizations to form, flouting the laws of their pro-life neighbors.”

NEW YORK DOCTOR ALLEGEDLY PRESCRIBED TO A PATIENT IN LOUISIANA THROUGH TELEMEDICYCY

Mifepristone boxes used in medical abortions. (Evelyn Hockstein/Reuters, File)

Family Research Council President Tony Perkins called the decision “great news for unborn children” and added that the issue “must be brought before the U.S. Supreme Court soon.”

Pro-choice advocates harshly criticized the decision.

New York Attorney General Letitia James called the decision “yet another brutal attack on access to abortion,” saying mifepristone is “safe, effective and necessary.”

“Restrictions on abortion care are restrictions on life-saving health care,” he added.

As Fox News Digital previously reported, a federal judge last month temporarily allowed mifepristone to be sold by mail order while legal challenges and federal review efforts continue.

PRO-LIFE MOVEMENT FACES HIGH ABORTION RATES THREE YEARS AFTER DOBBS

Pro-life supporters hold signs outside the Supreme Court in Washington DC (Olivier Douliery/AFP via Getty Images, File)

Judge David C. Joseph has previously warned against “government through litigation,” emphasizing that the FDA’s ongoing safety review, not litigation, is needed to determine long-term policy.

This review is ongoing, with the Department of Health and Human Services and the FDA tasked with reviewing the safety data, adverse events, and regulatory framework for mifepristone.

CLICK TO DOWNLOAD FOX NEWS APPLICATION

Louisiana Attorney General Liz Murrill argued that the policy caused “irreparable harm every day” it remained in effect and warned that the expanded access was designed to “reach jurisdictions like Louisiana” despite state-level abortion restrictions.

Friday’s decision now sets up a possible appeal to the Supreme Court, where a new challenge to federal authority over abortion drug regulation could come to the fore.

The Associated Press contributed to this report.